AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23165381 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight measurement
Number of subjects: 10
Study 20850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of intake of fruits (F)
Number of subjects: 72
Study 20850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of intake of reduced-calorie snack foods (RCSF)
Number of subjects: 72
Study 20850055 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial frequency of intake of vegetables (V)
Number of subjects: 72
Study 17437343 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oral calcium and vitamin D supplementation starting on postoperative day 1
Number of subjects: 487
Study 17437343 — intervention group
Group type: COMPARATOR
Intervention: No routine oral calcium and vitamin D supplementation
Number of subjects: 487
Study 15839866 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 92
Study 15839866 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 92
Study 11865132 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine (9-30 mg; mean dosage 16 mg)
Number of subjects: 15
Study 11865132 — intervention group
Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 15
Study 10467608 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (30 mmol/d of leucine, isoleucine, and valine)
Number of subjects: 19
Study 10467608 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 mmol/d of glycine, serine, and alanine)
Number of subjects: 19
Study 10467608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 1377036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (total greater than 5 x 10(6) kallikrein inactivator units [KIU])
Number of subjects: 1784
Study 1377036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin administration)
Number of subjects: 1784
Study 6714602 — intervention group
Group type: EXPERIMENTAL
Intervention: New solution containing mainly sodium sulfate and polyethylene glycol (solution II)
Number of subjects: 240
Study 6714602 — intervention group
Group type: COMPARATOR
Intervention: Balanced standard electrolyte solution (solution I)
Number of subjects: 240
Study 31375087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (two 375 mg/m2 doses, maximum dose: 500 mg)
Number of subjects: 0
Study 31375087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29468764 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin 500 mg/day
Number of subjects: 64
Study 26731258 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (to induce low or high postprandial glycemia)
Number of subjects: 71
Study 26731258 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 71
Study 26731258 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial hyperglycemia in T2D patients
Number of subjects: 71
Study 25711331 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 230
Study 25711331 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 230
Study 23685539 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy estimation of rapid cardiac rhythms preceding ICD shocks
Number of subjects: 119
Study 23685539 — intervention group
Group type: COMPARATOR
Intervention: ICD shocks delivered for VT/ventricular fibrillation
Number of subjects: 119
Study 23685539 — intervention group
Group type: COMPARATOR
Intervention: ICD shocks delivered for atrial fibrillation (AF)
Number of subjects: 119
Study 23685539 — intervention group
Group type: COMPARATOR
Intervention: ICD shocks delivered for supraventricular tachycardia
Number of subjects: 119
Study 20397880 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course on Cognitive Behavioral Therapy (CBT)
Number of subjects: 174
Study 17545193 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral DHEA
Number of subjects: 60
Study 17545193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16767613 — intervention group
Group type: COMPARATOR
Intervention: Generic aerobic interval training (running)
Number of subjects: 40
Study 16767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific aerobic interval training (small-sided games)
Number of subjects: 40
Study 12760702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled resin composite inserts
Number of subjects: 48
Study 12760702 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature resin composite inserts
Number of subjects: 48
Study 12760702 — intervention group
Group type: COMPARATOR
Intervention: Conventional bulk insertion (Control Group)
Number of subjects: 48
Study 10948809 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal corticosteroids (flunisolide)
Number of subjects: 44
Study 10948809 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine nasal spray (azelastine hydrochloride)
Number of subjects: 44
Study 9408667 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge service
Number of subjects: 92
Study 9408667 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 92
Study 8495154 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified paediatric resuscitation chart
Number of subjects: 31
Study 8495154 — intervention group
Group type: COMPARATOR
Intervention: Oakley chart
Number of subjects: 31
Study 3542982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid parenteral injections of fluphenazine hydrochloride
Number of subjects: 16
Study 3542982 — intervention group
Group type: COMPARATOR
Intervention: Oral doses of fluphenazine hydrochloride
Number of subjects: 16
Study 29504794 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy (ERT)
Number of subjects: 53
Study 29504794 — intervention group
Group type: COMPARATOR
Intervention: Modified Attention Control (MAC)
Number of subjects: 53
Study 24947537 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic support in the form of a voucher
Number of subjects: 0
Study 22706942 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with knee OA
Number of subjects: 33
Study 22706942 — intervention group
Group type: COMPARATOR
Intervention: Women with knee OA
Number of subjects: 33
Study 22706942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sexes (controlling for muscle volume)
Number of subjects: 33
Study 22706942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sexes (VA and contractile properties)
Number of subjects: 33
Study 20532506 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC insertion with skin colonisation monitoring
Number of subjects: 219
Study 20532506 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline colonisation
Number of subjects: 219
Study 20532506 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 219
Study 20532506 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 219
Study 18499079 — intervention group
Group type: EXPERIMENTAL
Intervention: High signal salience condition
Number of subjects: 176
Study 18499079 — intervention group
Group type: COMPARATOR
Intervention: Low signal salience condition
Number of subjects: 176
Study 18499079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-task self-reports of Task-Unrelated-Thoughts
Number of subjects: 176
Study 18499079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-task self-reports of Energetic Arousal
Number of subjects: 176
Study 15705997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg po qid)
Number of subjects: 18
Study 15705997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15705997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 18
Study 12837875 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement from clinician to breastfeed
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Lack of confidence in ability to breastfeed
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Early breastfeeding problems
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Asian race/ethnicity
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Lower maternal education
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Maternal depressive symptoms
Number of subjects: 1163
Study 12837875 — intervention group
Group type: COMPARATOR
Intervention: Returning to work or school by 12 weeks postpartum
Number of subjects: 1163
Study 10588556 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine without epinephrine
Number of subjects: 2
Study 8755747 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft tricortical iliac crest bone
Number of subjects: 132
Study 8755747 — intervention group
Group type: COMPARATOR
Intervention: Allograft bone
Number of subjects: 132
Study 8755747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 132
Study 1540488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 12
Study 1540488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 12
Study 1540488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6413114 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) plus cisplatin (DDP)
Number of subjects: 273
Study 6413114 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin regimens (various combinations)
Number of subjects: 273
Study 6413114 — intervention group
Group type: COMPARATOR
Intervention: Control group (DDP alone, thiotepa (TSPA) plus methotrexate (MTX))
Number of subjects: 273
Study 31638334 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase (HUK) combined with butylphthalide (NBP)
Number of subjects: 165
Study 31638334 — intervention group
Group type: COMPARATOR
Intervention: Edaravone (Eda) combined with butylphthalide (NBP)
Number of subjects: 165
Study 28486647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment
Number of subjects: 0
Study 26947239 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFCs)
Number of subjects: 1186
Study 26947239 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE results
Number of subjects: 1186
Study 26947239 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFCs in children with mild, moderate, and severe AD
Number of subjects: 1186
Study 26947239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1186
Study 26947239 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for food allergy
Number of subjects: 1186
Study 26947239 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation of AD
Number of subjects: 1186
Study 24385117 — intervention group
Group type: EXPERIMENTAL
Intervention: luliconazole cream 1%
Number of subjects: 256
Study 24385117 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 256
Study 22067762 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUD
Number of subjects: 88
Study 22067762 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUD
Number of subjects: 88
Study 18626697 — intervention group
Group type: EXPERIMENTAL
Intervention: SWAL-QoL-NL
Number of subjects: 152
Study 19126937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg daily)
Number of subjects: 11
Study 19126937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15189367 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 50 microg 24 h(‐1) two times per week + medroxyprogesterone 2.5 mg day(‐1) + alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Number of subjects: 18
Study 15189367 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Number of subjects: 18
Study 11898908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer and distant healing intervention
Number of subjects: 0
Study 11898908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9797792 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once a day for 4 days
Number of subjects: 10
Study 9797792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7658310 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO combined with adequate iron supplementation
Number of subjects: 0
Study 7658310 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. iron combined with rhEPO
Number of subjects: 0
Study 7658310 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO given s.c.
Number of subjects: 0
Study 7658310 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 300 U/kg rhEPO in healthy non-pregnant volunteers
Number of subjects: 0
Study 7658310 — intervention group
Group type: COMPARATOR
Intervention: i.v. iron alone
Number of subjects: 0
Study 2487544 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (0.2 mg/kg) infusion
Number of subjects: 12
Study 2487544 — intervention group
Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 12
Study 47949 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 120
Study 47949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 47949 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 120
Study 30445841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan plus lisinopril)
Number of subjects: 895
Study 30445841 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (losartan)
Number of subjects: 895
Study 26464072 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia presentation (MP) group
Number of subjects: 93
Study 26464072 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional verbal consent)
Number of subjects: 93
Study 26071565 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 40
Study 26071565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22620494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI), 300 mg twice daily for 28 days
Number of subjects: 20
Study 21694613 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/d
Number of subjects: 951
Study 21694613 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/d
Number of subjects: 951
Study 21694613 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/d
Number of subjects: 951
Study 21694613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study 18266876 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported mandibular overdentures (n=49)
Number of subjects: 97
Study 18266876 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (n=48)
Number of subjects: 97
Study 16242910 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration with expectation of analgesia
Number of subjects: 19
Study 16242910 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 19
Study 16242910 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including affective qualities of pain and internal affective state
Number of subjects: 19
Study 12705488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied at P6 point half an hour before surgery
Number of subjects: 50
Study 12705488 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with acupressure band tied on P6 point but bead placed away from P6 point
Number of subjects: 50
Study 10766682 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10, 200 mg/d
Number of subjects: 55
Study 10766682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8612390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times a day)
Number of subjects: 12
Study 8612390 — intervention group
Group type: COMPARATOR
Intervention: Tacrine (40 mg) alone
Number of subjects: 12
Study 1597980 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic systemic perfusion (35 degrees to 37 degrees C; n = 73)
Number of subjects: 146
Study 1597980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 gm intravenously; n = 63)
Number of subjects: 146
Study 1597980 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (15 gm intravenously; n = 63)
Number of subjects: 146
Study 1597980 — intervention group
Group type: COMPARATOR
Intervention: Warm control patients (no drug)
Number of subjects: 146
Study 1597980 — intervention group
Group type: COMPARATOR
Intervention: Cold control patients (no drug; n = 20)
Number of subjects: 146
Study 1597980 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic systemic perfusion, tranexamic acid, and epsilon‐aminocaproic acid
Number of subjects: 146
Study 6338768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 1 (naphazoline hydrochloride + antazoline phosphate)
Number of subjects: 89
Study 6338768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 2 (naphazoline hydrochloride + pheniramine maleate)
Number of subjects: 89
Study 6338768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 3 (naphazoline hydrochloride + antazoline phosphate or pheniramine maleate)
Number of subjects: 89
Study 30136858 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-Style Simplified t'ai chi exercise for 3 months
Number of subjects: 208
Study 30136858 — intervention group
Group type: COMPARATOR
Intervention: General daily lifestyle intervention
Number of subjects: 208
Study 28121044 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h prophylaxis
Number of subjects: 464
Study 28121044 — intervention group
Group type: COMPARATOR
Intervention: 72 h prophylaxis
Number of subjects: 464
Study 26598919 — intervention group
Group type: EXPERIMENTAL
Intervention: Kan Jang (KJ) oral solution (30 ml/day; 762 mg genuine extracts with standardized contents of 0.2 mg/ml vasicine, 0.8 mg/ml chicoric acid, and 0.03 mg/ml eleutherosides B and E)
Number of subjects: 177
Study 26598919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride (24 mg/30 ml/day)
Number of subjects: 177
Study 26598919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 177
Study 24158631 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF drainage
Number of subjects: 26
Study 22468716 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative implementation intentions
Number of subjects: 257
Study 22468716 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 257
Study 22468716 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-only
Number of subjects: 257
Study 22468716 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 257
Study 19747359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy and short-term sequential digital dermoscopy imaging (SDDI)
Number of subjects: 63
Study 19747359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy and SDDI
Number of subjects: 63
Study 17080004 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 days of antibiotics
Number of subjects: 401
Study 17080004 — intervention group
Group type: COMPARATOR
Intervention: 15 days of antibiotics
Number of subjects: 401
Study 17080004 — intervention group
Group type: COMPARATOR
Intervention: 8 vs. 15 days of antibiotics
Number of subjects: 401
Study 16338560 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular bending ring (CBR)
Number of subjects: 92
Study 16338560 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 92
Study 16338560 — intervention group
Group type: COMPARATOR
Intervention: Capsular measuring ring (CMR) alone
Number of subjects: 92
Study 12456201 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholly stochastic cost-effectiveness analysis
Number of subjects: 0
Study 12456201 — intervention group
Group type: COMPARATOR
Intervention: Baseline clinical trial design
Number of subjects: 0
Study 9607017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib (SB) + DTPw in the same syringe
Number of subjects: 230
Study 9607017 — intervention group
Group type: COMPARATOR
Intervention: Hib (SB) + DTPw separately
Number of subjects: 230
Study 9607017 — intervention group
Group type: COMPARATOR
Intervention: Hib (PM) + DTPw separately
Number of subjects: 230
Study 8582502 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-treated sperm
Number of subjects: 41
Study 8582502 — intervention group
Group type: COMPARATOR
Intervention: TEST-yolk treated sperm
Number of subjects: 41
Study 2094341 — intervention group
Group type: COMPARATOR
Intervention: 150 micrograms selenium
Number of subjects: 33
Study 2094341 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms selenium daily for 14 days
Number of subjects: 33
Study 2094341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 639229 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg intravenously followed by 320 mg orally over 27 hours)
Number of subjects: 95
Study 639229 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 95
Study 30807423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary use
Number of subjects: 114
Study 27639190 — intervention group
Group type: EXPERIMENTAL
Intervention: P/EVL
Number of subjects: 185
Study 27639190 — intervention group
Group type: COMPARATOR
Intervention: P/CsA
Number of subjects: 185
Study 25786106 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (100mg)
Number of subjects: 96
Study 25786106 — intervention group
Group type: COMPARATOR
Intervention: Control snack bars
Number of subjects: 96
Study 22773237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nathanson liver retractor
Number of subjects: 60
Study 22773237 — intervention group
Group type: EXPERIMENTAL
Intervention: liver suspension tape
Number of subjects: 60